Company news
Voyager Therapeutics, Inc. news in 2022
Voyager Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
December 13, 2022
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
November 7, 2022
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
October 31, 2022
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
October 10, 2022
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
October 3, 2022
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
October 2, 2022
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
September 6, 2022
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
August 3, 2022
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
August 2, 2022
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
July 27, 2022
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
May 18, 2022
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
May 3, 2022
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
May 2, 2022
Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
March 21, 2022
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
March 7, 2022
Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
February 2, 2022